Slideshow 10 prescription drugs losing patent protection in 2016

Published
  • February 24 2016, 12:01am EST
11 Images Total

10 drugs to watch in 2016

Generic drugs are usually significantly cheaper for plan sponsors than brand-name drugs. Here’s a look at 10 drugs coming off patent in 2016. And although the FDA hasn’t yet approved generics for many of the following blockbuster drugs that are coming off patent this year, in most cases there are generics in the pipeline, according to Dickson Data Blog.

1. Humira

Used for: Rheumatoid arthritis

Manufactured by: Abbvie

Estimated annual sales: $12.54 billion

Generic approved: Biosimilars in the pipeline; no generic approved

Content Continues Below


2. Crestor

Used for: Lower bad cholesterol (LDL), raise good cholesterol (HDL)

Manufactured by: AstraZeneca

Estimated annual sales: $6.4 billion

Generic approved: N/A

3. Benicar

Used for: High blood pressure

Manufactured by: Daiichi Sankyo

Estimated annual sales: $2.6 billion

Generic approved: N/A

Content Continues Below


4. Zetia

Used for: High cholesterol

Manufactured by: Merck

Estimated annual sales: $2.6 billion

Generic approved: N/A

5. Seroquel XR

Used for: Schizophrenia and bipolar disorder

Manufactured by: AstraZeneca

Estimated annual sales: $1.3 billion

Generic approved: N/A

Content Continues Below


6. AcipHex Sprinkle

Used for: Acid reflux, ulcers

Manufactured by: Eisai

Estimated annual sales: $1.2 billion

Generic approved: November 2013

7. Epzicon

Used for: HIV

Manufactured by: Viiv Healthcare

Estimated annual sales: $1.1 billion

Generic approved: N/A

Content Continues Below


8. Kaletra

Used for: HIV

Manufactured by: Abbott

Estimated annual sales: $1 billion

Generic approved: N/A

9. Norvir

Used for: HIV

Manufactured by: Abbott

Estimated annual sales: $962 million

Generic approved: Jan. 15, 2015

Content Continues Below


10. Ambisome

Used for: Anti-fungal medicine

Manufactured by: Gilead

Estimated annual sales: $493 million

Generic approved: N/A